Oncology-focused drug development company Kazia Therapeutics (ASX: KZA)has recruited its first patient into a Phase II study of investigational new drug paxalisib for the treatment of newly-diagnosed and recurrent glioblastoma.
The two-year study has been initiated at Weill Cornell Medical Centre in New York and will investigate the efficacy of paxalisib in combination with diabetic medication metformin and a ketogenic diet across two arms with an initial cohort of 16 patients each.
Read more.
